325 related articles for article (PubMed ID: 34717019)
1. The role of PI3'-lipid signalling in melanoma initiation, progression and maintenance.
Parkman GL; Foth M; Kircher DA; Holmen SL; McMahon M
Exp Dermatol; 2022 Jan; 31(1):43-56. PubMed ID: 34717019
[TBL] [Abstract][Full Text] [Related]
2. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.
Rodgers SJ; Ferguson DT; Mitchell CA; Ooms LM
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28082369
[TBL] [Abstract][Full Text] [Related]
3. RAC1mutation is not a predictive biomarker for PI3'-kinase-β-selective pathway-targeted therapy.
Foth M; Parkman G; Battistone B; McMahon M
Pigment Cell Melanoma Res; 2020 Sep; 33(5):719-730. PubMed ID: 32406574
[TBL] [Abstract][Full Text] [Related]
4. The INPP4B paradox: Like PTEN, but different.
Hamila SA; Ooms LM; Rodgers SJ; Mitchell CA
Adv Biol Regul; 2021 Dec; 82():100817. PubMed ID: 34216856
[TBL] [Abstract][Full Text] [Related]
5. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
Silva JM; Bulman C; McMahon M
Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.
Silva JM; Deuker MM; Baguley BC; McMahon M
Pigment Cell Melanoma Res; 2017 May; 30(3):353-367. PubMed ID: 28233937
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol (3,4) bisphosphate-specific phosphatases and effector proteins: A distinct branch of PI3K signaling.
Li H; Marshall AJ
Cell Signal; 2015 Sep; 27(9):1789-98. PubMed ID: 26022180
[TBL] [Abstract][Full Text] [Related]
8. Signalling through Class I PI3Ks in mammalian cells.
Hawkins PT; Anderson KE; Davidson K; Stephens LR
Biochem Soc Trans; 2006 Nov; 34(Pt 5):647-62. PubMed ID: 17052169
[TBL] [Abstract][Full Text] [Related]
9. PI3K/Akt signalling pathway and cancer.
Fresno Vara JA; Casado E; de Castro J; Cejas P; Belda-Iniesta C; González-Barón M
Cancer Treat Rev; 2004 Apr; 30(2):193-204. PubMed ID: 15023437
[TBL] [Abstract][Full Text] [Related]
10. Cardiac regulation by phosphoinositide 3-kinases and PTEN.
Oudit GY; Penninger JM
Cardiovasc Res; 2009 May; 82(2):250-60. PubMed ID: 19147653
[TBL] [Abstract][Full Text] [Related]
11. PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.
Haddadi N; Lin Y; Travis G; Simpson AM; Nassif NT; McGowan EM
Mol Cancer; 2018 Feb; 17(1):37. PubMed ID: 29455665
[TBL] [Abstract][Full Text] [Related]
12. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
[TBL] [Abstract][Full Text] [Related]
13. PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma.
Ye Y; Jin L; Wilmott JS; Hu WL; Yosufi B; Thorne RF; Liu T; Rizos H; Yan XG; Dong L; Tay KH; Tseng HY; Guo ST; de Bock CE; Jiang CC; Wang CY; Wu M; Zhang LJ; Hersey P; Scolyer RA; Zhang XD
Nat Commun; 2013; 4():1508. PubMed ID: 23443536
[TBL] [Abstract][Full Text] [Related]
14. Revisiting PI3-kinase signalling in angiogenesis.
Kobialka P; Graupera M
Vasc Biol; 2019; 1(1):H125-H134. PubMed ID: 32923964
[TBL] [Abstract][Full Text] [Related]
15. Advances in development of phosphatidylinositol 3-kinase inhibitors.
Kong D; Yamori T
Curr Med Chem; 2009; 16(22):2839-54. PubMed ID: 19689267
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl.
Mokhtari D; Al-Amin A; Turpaev K; Li T; Idevall-Hagren O; Li J; Wuttke A; Fred RG; Ravassard P; Scharfmann R; Tengholm A; Welsh N
Diabetologia; 2013 Jun; 56(6):1327-38. PubMed ID: 23462796
[TBL] [Abstract][Full Text] [Related]
17. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells.
Beresford SA; Davies MA; Gallick GE; Donato NJ
J Interferon Cytokine Res; 2001 May; 21(5):313-22. PubMed ID: 11429162
[TBL] [Abstract][Full Text] [Related]
19. Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cgamma pathway.
Marshall AJ; Niiro H; Yun TJ; Clark EA
Immunol Rev; 2000 Aug; 176():30-46. PubMed ID: 11043766
[TBL] [Abstract][Full Text] [Related]
20. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease.
Oudit GY; Sun H; Kerfant BG; Crackower MA; Penninger JM; Backx PH
J Mol Cell Cardiol; 2004 Aug; 37(2):449-71. PubMed ID: 15276015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
